Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

554
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
554
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

410
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
410
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

967
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
967
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

408
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
408
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

1.0K
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
1.0K
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

3.1K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
3.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessing peripheral oxytocin and cortisol levels and epigenetic variations of oxytocin receptor and glucocorticoid receptor genes in school-aged preterm-born children.

Progress in neurobiology·2026
Same author

Cerebral Oximetry in Extremely Preterm Infants: 2-Year Follow-Up of the SafeBoosC-III Randomized Clinical Trial.

JAMA pediatrics·2026
Same author

Subclinical but significant: A multi-informant comparative study on early socio-emotional difficulties in preterm preschoolers.

Child and adolescent psychiatry and mental health·2026
Same author

Treatment guided by cerebral oximetry in newborns receiving invasive mechanical ventilation: study protocol for step one of the SafeBoosC-IIIv randomised clinical trial.

Trials·2026
Same author

Toward automated neonatal EEG analysis: multi-center validation of a reliable deep learning pipeline.

Frontiers in neuroscience·2026
Same author

Attaining neurodevelopmental milestones and exposures to fine particulate matter and environmental green spaces.

Environmental health : a global access science source·2026

Related Experiment Video

Updated: May 4, 2026

Intravenous Injections in Neonatal Mice
05:17

Intravenous Injections in Neonatal Mice

Published on: November 11, 2014

59.8K

Developmental pharmacokinetics in neonates.

Karel Allegaert1, Maissa Rayyan, Sophie Vanhaesebrouck

  • 1Neonatal Intensive Care Unit, Division of Woman and Child, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium. karel.allegaert@uz.kuleuven.ac.be.

Expert Review of Clinical Pharmacology
|January 16, 2014
PubMed
Summary

Drug disposition in neonates is highly variable due to immature organ function and genetic factors. Understanding these developmental changes is crucial for safe and effective pediatric drug prescribing.

More Related Videos

A Neonatal Rodent Model of Retroorbital Vein Injection
04:39

A Neonatal Rodent Model of Retroorbital Vein Injection

Published on: February 23, 2024

9.1K
Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods
09:04

Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods

Published on: September 10, 2018

8.4K

Related Experiment Videos

Last Updated: May 4, 2026

Intravenous Injections in Neonatal Mice
05:17

Intravenous Injections in Neonatal Mice

Published on: November 11, 2014

59.8K
A Neonatal Rodent Model of Retroorbital Vein Injection
04:39

A Neonatal Rodent Model of Retroorbital Vein Injection

Published on: February 23, 2024

9.1K
Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods
09:04

Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods

Published on: September 10, 2018

8.4K

Area of Science:

  • Pharmacology
  • Neonatal Medicine
  • Drug Metabolism

Background:

  • Neonatal drug administration requires understanding developmental drug disposition.
  • Significant interindividual variability exists in drug disposition among neonates.
  • Renal and metabolic clearance pathways are immature in neonates, impacting drug elimination.

Purpose of the Study:

  • To review the developmental aspects of drug disposition in neonates.
  • To highlight factors contributing to interindividual variability in neonatal drug clearance.
  • To discuss clinical research tools for assessing maturational changes in drug disposition.

Main Methods:

  • Review of existing clinical research and literature on neonatal drug disposition.
  • Analysis of factors influencing drug clearance, including age, route of administration, and genetics.
  • Discussion of population pharmacokinetic approaches.

Main Results:

  • Renal drug elimination is decreased due to immature renal function.
  • Metabolic clearance is dependent on specific enzyme ontogeny and postmenstrual/postnatal age.
  • Age, route of administration, comorbidities, co-administered drugs, and genetic polymorphisms contribute to variability.

Conclusions:

  • Integrating knowledge of neonatal drug disposition into clinical practice is essential for safe prescribing.
  • Legal initiatives like the EU's Paediatric Drug Regulation and research tools like population pharmacokinetics are key drivers for progress.
  • Further research and clinical integration are needed to optimize neonatal pharmacotherapy.